Peter Greenleaf compensation by year
Aurinia Pharmaceuticals Summary Compensation Table · all 7 fiscal years held| Component | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Salary | $438,258 | $673,400 | $723,905 | $791,228 | $822,877 | $822,877 | $822,877 |
| Bonus | $250,000 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $0 | $1,534,992 | $0 | $3,750,002 | $8,999,997 | $4,825,917 | $1,965,321 |
| Option awards | $4,176,172 | $7,753,906 | $0 | $3,752,009 | $0 | $0 | $2,193,189 |
| Non-equity incentive | $368,137 | $707,070 | $506,734 | $498,474 | $710,760 | $720,017 | $864,021 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $4,063 | $9,914 | $10,182 | $45,684 | $39,725 | $49,086 | $13,182 |
| Total | $5,236,630 | $10,679,282 | $1,240,821 | $8,837,397 | $10,573,359 | $6,417,897 | $5,858,590 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Aurinia Pharmaceuticals Inc. DEF 14A filed April 21, 2026, accession 0001600620-26-000039, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Aurinia Pharmaceuticals Inc. filed document, accession 0001600620-26-000039. Every figure is read from that document and cited to the page and table it appears in. Filed April 21, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 441,026 | $7,034,365 | — |
| RSU | 290,728 | $4,637,112 | — |
| RSU | 222,469 | $3,548,381 | — |
| RSU | 82,692 | $1,318,937 | — |
| Option | 443,973 | — | $7.55 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Aurinia Pharmaceuticals Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Change-in-control & termination
estimated payments Aurinia Pharmaceuticals discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary termination without cause | $1,234,316 | — | $30,414 | $1,264,730 |
| Change in control and involuntary termination | $1,645,754 | $40,406,579 | $30,414 | $42,082,747 |
Per the Potential Payments Upon Termination or Change in Control table in Aurinia Pharmaceuticals Inc.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
Aurinia Pharmaceuticals’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Peter Greenleaf · this page | Former Chief Executive Officer | $5,858,590 |
| Matthew Donley | Former Chief Operating Officer | $2,237,088 |
| Stephen Robertson | Chief Legal Officer, Corporate Secretary and Chief Compliance Officer | $2,126,510 |
| Joseph Miller | Former Chief Financial Officer | $2,102,747 |
| Gregory Keenan | Former Chief Medical Officer | $1,774,241 |
Board service
Aurinia Pharmaceuticals board · FY2021–FY2022How this board is paid
Company policy: Aurinia Pharmaceuticals pays directors a $45,000 cash retainer and $200,000 in Options. As stated in Aurinia Pharmaceuticals's FY2022 proxy.
The full Aurinia Pharmaceuticals compensation record
free company briefThis page is one person within Aurinia Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Aurinia Pharmaceuticals proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Aurinia Pharmaceuticals's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Aurinia Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order AUPH
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.